Research area :
- Tyrosine kinase variants in cancer; Zebrafish as an alternate animal model for tyrosine kinase dysfunction and cancer
Education & Training :
- 1998–2004: Ph.D. in Pharmacology & Toxicology, University of Mississippi Medical Center
Professional Experience :
- 2005–2008: Post-doctoral fellow, State University of New York at Stony Brook
- 2008–2013: Senior Research Scientist, Dr. Reddy’s Institute of Life Sciences
- 2013- : Principal Research Scientist, Dr. Reddy’s Institute of Life Sciences
Research Interests :
- Tyrosine kinases are a major family of messengers in cell growth pathways. Drugs selectively inhibiting oncogenic tyrosine kinases (tyrosine kinase inhibitors or TKIs) have been shown to be clinically successful as targeted anti-cancer therapies. Access to TKIs in India and in several other countries is severely limited; evolution of drug resistance and occurrence of variant TKs is a problem. Kiranam Chatti’s work at DRILS is focused on-
i) developing genetically engineered TK-mutant zebrafish as alternative animal models to facilitate in vivo evaluation of TKIs, and
ii) using computational and experimental methods to study TK variants.
Use of CRISPR-Cas9 technology as a tool to generate genetically modified zebrafish and cell lines is a recently initiated effort
Link to Google Scholar page :